Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36900295/
Ibrutinib revolutionized the CLL treatment approach and prognosis demonstrating its efficacy and safety even at extended follow-up. During the last few years, several next-generation inhibitors have been developed to overcome...
Conclusions/Relevance: New mechanisms for BTK inhibition are under investigations in patients progressing with both covalent and non-covalent BTK and BCl2 inhibitors. Here we summarize and discuss results from main experiences on irreversible and reversable BTK inhibitors in CLL.
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36377973/
Treatment with covalent Bruton tyrosine kinase inhibitors (BTKi) represents an important advance in the management of relapsed or refractory mantle cell lymphoma, but these treatments are not curative and many...
Conclusions: This phase III, head-to-head, randomized study (NCT04662255) will evaluate whether pirtobrutinib is superior to investigator’s choice of covalent BTKi in patients with previously treated, BTKi-naive mantle cell lymphoma.
-
Leukemia and Lymphoma Connect2yrKey Points • Source: Future Medicine • Relevance: “Pirtobrutinib is well tolerated and has demonstrated promising efficacy in patients with poor prognosis B-cell malignancies following prior therapy, including covalent BTKi. This phase III, head-to-head, Show More
SOHO State of the Art Updates and Next Questions | Infections in Chronic Lymphocytic Leukemia Patients: Risks and Management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36868914/
Although chronic lymphocytic leukemia (CLL) is a malignancy characterized by accumulation of tumor cells in the blood, bone marrow, lymph nodes and secondary lymphoid tissues, the hallmark of the disease...
Conclusions: The CLL-TIM algorithm is currently being used for selection of patients for the clinical trial PreVent-ACaLL (NCT03868722), testing whether short-term treatment with the BTK inhibitor acalabrutinib and the BCL-2 inhibitor venetoclax can improve immune function and decrease the risk of infections for this high-risk patient...
Pirtobrutinib
Source : https://www.ncbi.nlm.nih.gov/books/NBK589166/
No information is available on the clinical use of pirtobrutinib during breastfeeding. It is 96% bound to plasma proteins, so concentrations in milk are likely low. The manufacturer recommends that...
Conclusions: No information is available on the clinical use of pirtobrutinib during breastfeeding. It is 96% bound to plasma proteins, so concentrations in milk are likely low. The manufacturer recommends that breastfeeding be discontinued during pirtobrutinib therapy and for 1 week after the last dose.
A Multicenter Analysis of the Outcomes with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36809796/
To report the activity of venetoclax in patients with relapsed mantle cell lymphoma (MCL), we identified 81 patients treated with venetoclax monotherapy (n=50, 62%) or in combination with a BTK...
Conclusions: In high-risk patients with relapsed MCL, most of whom received prior BTKi, venetoclax resulted in ORR of 40% and median PFS of 3.7 months. Patients with MCL who initiate venetoclax should be closely monitored for tumor lysis syndrome.